COMPAZINE
LOE ApproachingNDARECTALSUPPOSITORY
Approved
Jan 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is a first-generation antipsychotic and antiemetic approved in 1959 as a rectal suppository formulation. The exact mechanism of action involves dopamine antagonism in the chemoreceptor trigger zone and vomiting center. It is used primarily for nausea, vomiting, and psychiatric conditions in patients who cannot tolerate oral or parenteral routes.
LOE Approaching
Declining market presence with moderate competitive pressure (30/100) signals a mature, potentially downsizing brand team focused on managed care and cost optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining COMPAZINE offers limited growth opportunity; the product is in lifecycle decline with minimal clinical development and low job availability (0 linked roles). Career value lies in managed care negotiation, legacy product optimization, and cost-containment strategy rather than innovation or market expansion.
Brand ManagerProduct Manager
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.